Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively
- PMID: 40549942
- DOI: 10.5435/JAAOS-D-25-00439
Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively
Abstract
Background: Patients with type II diabetes mellitus (T2DM) are known to have inferior postoperative outcomes after open reduction and internal fixation (ORIF) of ankle fractures. Semaglutide (the active agent in Ozempic) has encouragingly been associated with improved postoperative outcomes across multiple elective orthopaedic surgeries; however, this has not been assessed for patients with T2DM undergoing ankle fracture ORIF.
Methods: Adult patients with T2DM who underwent ankle fracture ORIF were identified from the 2010-Q1 2023 PearlDiver M170Ortho database. Exclusion criteria included the following: age younger than 18, high-energy injury mechanisms, concomitant tibial plafond fracture, other non-ankle traumatic injuries, neoplastic or infectious diagnoses within 30 days preoperatively, and those with <90 days of follow-up. Patients with T2DM who used semaglutide within 1 year before ankle fracture ORIF were identified and matched 1:1 with patients with T2DM who had not used semaglutide based on age, sex, Elixhauser Comorbidity Index, end-organ diabetes complications, obesity (body mass index <30 vs. >30), insulin use, metformin use, sodium-glucose cotransport-2 inhibitor use, and insurance plan. The odds of 90-day adverse events were compared by multivariable logistic regression controlling for age, sex, and Elixhauser Comorbidity Index. Bonferroni correction of P < 0.005 was used to reduce the risk of type I error.
Results: Among patients with T2DM undergoing ankle fracture ORIF, semaglutide use was noted for 2,700 patients (2.73%). After matching, there were 804 (+)semaglutide and 804 (-)semaglutide patients. On multivariable analysis, (+)semaglutide patients had significantly lower odds of 90-day deep vein thrombosis (odds ratio [OR] 0.24), myocardial infarction (OR 0.34), surgical site infection (OR 0.30), sepsis (OR 0.38), pneumonia (OR 0.27), urinary tract infection (OR 0.27), wound dehiscence (OR 0.31), and emergency department visit (OR 0.45; P < 0.001 for all).
Conclusion: This study found reductions in 90-day cardiovascular and infectious complications after ORIF of ankle fractures for patients with T2DM using semaglutide preoperatively as part of their glycemic control regimen.
Level of evidence: Level III.
Copyright © 2025 by the American Academy of Orthopaedic Surgeons.
References
-
- Scheer RC, Newman JM, Zhou JJ, et al.: Ankle fracture epidemiology in the United States: Patient-related trends and mechanisms of injury. J Foot Ankle Surg 2020;59:479-483.
-
- Vanderkarr MF, Ruppenkamp JW, Vanderkarr M, Parikh A, Holy CE, Putnam M: Incidence, costs and post-operative complications following ankle fracture—A US claims database analysis. BMC Musculoskelet Disord 2022;23:1129.
-
- Fenelon C, Galbraith JG, Fahey T, Kearns SR: The operative treatment of ankle fractures: A 10-year retrospective study of 1529 patients. J Foot Ankle Surg 2021;60:663-668.
-
- Kannus P, Palvanen M, Niemi S, Parkkari J, Järvinen M: Increasing number and incidence of low-trauma ankle fractures in elderly people: Finnish statistics during 1970-2000 and projections for the future. Bone 2002;31:430-433.
-
- Wang H, Ba Y, Xing Q, Du JL: Diabetes mellitus and the risk of fractures at specific sites: A meta-analysis. BMJ Open 2019;9:e024067.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
